News | Heart Valve Technology | January 06, 2017

First Pennsylvania Patient Enrolled in RECHORD Trial of Neochord DS1000 System

Nationwide trial designed to test minimally invasive treatment for mitral regurgitation

RECHORD Trial, Neochord DS1000 System, mitral regurgitation, PinnacleHealth, first Pennsylvania patient

January 6, 2017 — The RECHORD trial allows cardiovascular surgeons to replace damaged string-like tendons, called chordae, through a small incision while the heart is beating. The trial compares outcomes from this minimally invasive procedure to traditional open-heart mitral valve surgery, which requires the chest to be cracked. Specialized imaging is used to place the artificial chordae. PinnacleHealth is one of only 20 sites in the nation and the only hospital in Pennsylvania selected to participate in the trial. Up to 450 patients will be enrolled into the randomized trial.

In a healthy heart, the chordae holds heart valves in place. Over time, the tendons may stretch or break, leading to serious heart conditions, such as mitral regurgitation. Mitral valve regurgitation refers to the mitral valve not closing tightly, which does not allow blood to move through the heart or to the rest of the body as efficiently as it should. Symptoms may include feeling tired or being out of breath.

During traditional surgery to repair damaged mitral valve chordae, surgeons often have to go through the sternum and put the heart on bypass to manually place sutures. With the NeoChord System, doctors can use the device to repair mitral valve prolapse via a transapical, off-pump procedures. Placement is confirmed with imaging (echocardiogram) and then a preloaded surgical suture is deployed.

This new trial at PinnacleHealth is led by Mubashir Mumtaz, M.D., FACS, FACC, chief of cardiothoracic surgery and surgical director of structural heart, and Hemal Gada, M.D., MBA, medical director of structural heart.

"With this investigational device, we are offering new, minimally invasive mitral valve therapies to patients in our community before it is available elsewhere," said Mumtaz.

For more information: www.neochord.com

Related Content

Intensive Glycemic Control Program Produces Significant Per-Patient Cost Savings for CABG Surgery
News | Cardiovascular Surgery| May 25, 2017
A new study from Emory University observed a near-20 percent reduction in perioperative complications, a 1.2-day...
Edwards Lifesciences Centera self expanding transcatheter (TAVR) valve
News | Heart Valve Technology| May 24, 2017
May 24, 2017 — Late-breaking data presented at EuroPCR 2017 demonstrating excellent clinical outcomes for...
3-D Echo Image Analysis With Philips' HeartModel A.I. is Accurate and Reproducible
News | Cardiovascular Ultrasound| May 24, 2017
May 24, 2017 — Philips recently announced the results from a global study indicating that automated...
Heart Failure Mortality Inversely Related to Wealth of Country
News | Heart Failure| May 24, 2017
Death in patients with heart failure is inversely related to the wealth of the country they live in, according to late...
ASE Announces Meeting Highlights for 28th Annual Scientific Sessions
News | Cardiovascular Ultrasound| May 23, 2017
May 23, 2017 — The American Society of Echocardiography (ASE) will host its 28th Annual Scientific Sessions, June 2-6
Shockwave Medical Announces CE Mark for Coronary Lithoplasty System and Activities at EuroPCR 2017
News | Cath Lab| May 23, 2017
Shockwave Medical announced last week CE Mark for the company’s Coronary Lithoplasty System for the treatment of...
New Paper Highlights Success of Advanced Treatments in Complex Aortic Aneurysm Repair
News | Endovascular Aortic Repair| May 23, 2017
Significant success has been achieved in treating complex proximal aneurysms using a combination of fenestrated and...
Risk of Heart Transplant Rejection Reduced by Desensitizing Patient Antibodies
News | Cardiovascular Surgery| May 23, 2017
The risk of heart transplant rejection can be reduced by desensitizing patient antibodies, according to research...
News | Heart Failure| May 22, 2017
Serelaxin failed to meet the primary endpoints of the phase 3 RELAX-AHF-2 trial, according to late-breaking results...
Overlay Init